"Efficacy and Safety of Levofloxacin vs Isoniazid in Latent Tuberculosis Infection in Liver Transplant Patients". (FLISH-ILT)
A multicenter, prospective, non-inferiority, randomized and open clinical trial comparing levofloxacin with isoniazid in the treatment of latent tuberculosis infection in patients eligible for liver transplantation.
Patients over 18 years of age on the waiting list for liver transplantation.
Sample size: n=870 patients.
Levofloxacin treatment of latent tuberculosis infection, begun while on the waiting list for liver transplantation, is safer and not less effective than isoniazid treatment begun after transplantation when liver function is stable.
Latent Tuberculosis Infection
Infection in Solid Organ Transplant Recipients
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||"A Prospective, Randomized, Comparative Clinical Trial of the Efficacy and Safety of Levofloxacin Versus Isoniazid in the Treatment of Latent Tuberculosis Infection in Liver Transplant Patients".|
- Difference in incidence of tuberculosis disease [ Time Frame: 18 months of follow-up ] [ Designated as safety issue: No ]A patient will be considered as having tuberculosis when Mycobacterium tuberculosis is isolated by culture or M. Tuberculosis DNA is isolated from a representative clinical sample, organ fluid or tissue by polymerase chain reaction. Also cases of histopathologically confirmed tuberculosis (caseating granulomas with/without demonstration of acid-alcohol resistant bacillus [BAAR]) and clinically compatible presentation will be accepted. Tuberculosis will be classified as pulmonary (pulmonary parenchymal involvement), extrapulmonary (involvement of different organs to the lung) or disseminated (involvement of at least two non-contiguous organs). Cases where tuberculosis is diagnosed on the basis of clinical and/or radiology suspicion and for whom the corresponding physician has prescribed a specific treatment will not be accepted.
- Mortality [ Time Frame: 18 months ] [ Designated as safety issue: Yes ]Number of deaths of any cause
- Toxicity [ Time Frame: During all the 18 months of follow-up ] [ Designated as safety issue: Yes ]Occurrence of grade 3 or 4 toxicities according to the grading (severity) scale of the National Cancer Institute Common Toxicity Criteria Version 4.0, NCI-CTC-AE v 4.0.
- Retransplantation [ Time Frame: 18 months ] [ Designated as safety issue: Yes ]A new liver transplantation during the follow-up
- Graft dysfunction [ Time Frame: 18 months ] [ Designated as safety issue: Yes ]Development of advanced graft fibrosis stages 3 and 4
- Transplant rejection [ Time Frame: 18 months ] [ Designated as safety issue: Yes ]The occurrence of acute rejection or chronic rejection as per conventional definitions during the follow-up.
- Safety [ Time Frame: 18 months ] [ Designated as safety issue: Yes ]
Drug tolerance will be evaluated by a clinical study interview and periodic analytical determinations which will include levels of transaminases (ALT and AST), alkaline phosphatase and gamma-GT, bilirubin, according to the study visit schedule.
All symptoms and laboratory results will be evaluated for severity according to the grading (severity) scale of the National Cancer Institute Common Toxicity Criteria Version 3.0, NCI-CTC-AE v 3.0.
|Study Start Date:||January 2012|
|Estimated Study Completion Date:||November 2015|
|Estimated Primary Completion Date:||November 2014 (Final data collection date for primary outcome measure)|
Levofloxacin 500 mg daily for 9 months starting on the waiting list for liver transplant
Active Comparator: Isoniazid
Isoniazid 300 mg/day for 9 months beginning after transplantation, when the "liver function is stable" and not before 3 months nor after 6 months
300 mg/day for 9 months beginning after transplantation, when the "liver function is stable" and not before 3 months nor after 6 months.
To demonstrate that the incidence of tuberculosis in patients with latent tuberculosis infection and treated with levofloxacin is not higher than that observed in patients treated with isoniazid.
- To demonstrate that the efficacy of levofloxacin is not limited by adverse effects, paying particular attention to hepatotoxicity.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01761201
|Complejo Hospitalario de Albacete||Recruiting|
|Contact: Jose Mª Moreno Planas, MD.PhD firstname.lastname@example.org|
|Principal Investigator: José María Moreno Planas, MD.PhD|
|Hospital Infanta Cristina,||Recruiting|
|Contact: Agustín Muñoz Sanz, MD.PhD Agus.muñozsanz@gmail.com|
|Principal Investigator: Agustín Muñoz Sanz, MD.PhD|
|Hospital Vall d'Hebron||Recruiting|
|Contact: Oscar Len, MD.PhD email@example.com|
|Principal Investigator: Oscar Len, MD.PhD|
|Contact: Asunción Moreno, MD.PhD firstname.lastname@example.org|
|Principal Investigator: Asunción Moreno, MD.PhD|
|Hospital de Cruces||Recruiting|
|Contact: Miguel Montejo, MD.PhD email@example.com|
|Principal Investigator: Miguel Montejo, MD.PhD|
|Complejo Hospitalario Universitario||Recruiting|
|Contact: Enrique Miguez, MD.PhD Enrique.firstname.lastname@example.org|
|Principal Investigator: Enrique Miguez, MD.PhD|
|Hospital Reina Sofía||Recruiting|
|Contact: Elisa Vidal, Md.PhD +34 011636957 Vidal.email@example.com|
|Principal Investigator: Elisa Vidal, Md.PhD|
|Hospital universitario Virgen de las Nieves||Recruiting|
|Contact: Miguel Angel López Ruz, MD.PhD firstname.lastname@example.org|
|Principal Investigator: Miguel Angel López Ruz, MD.PhD|
|Hospital Gregorio Marañón||Recruiting|
|Contact: Patricia Muñoz email@example.com|
|Principal Investigator: Patricia Muñoz, MD.PhD|
|Hospital Ramón y Cajal||Recruiting|
|Contact: Pilar Martín Dávila, MD.PhD firstname.lastname@example.org|
|Principal Investigator: Pilar Martín Dávila, MD.PhD|
|Hospital 12 de Octubre||Recruiting|
|Contact: Rafael san Juan, MD.PhD email@example.com|
|Principal Investigator: Rafael San Juan, MD.PhD|
|Hospital Universitario Puerta de Hierro||Recruiting|
|Contact: Isolina Baños Pérez, MD.PhD firstname.lastname@example.org|
|Principal Investigator: Isolina Baños Pérez, MD.PhD|
|Hospital Virgen de la Arrixaca||Recruiting|
|Contact: José Antonio Pons Miñano, MD.PhD email@example.com|
|Principal Investigator: José Antonio Pons Miñano, MD.PhD|
|Hospital Universitario Carlos Haya||Recruiting|
|Contact: Juan Rodrigo, MD.PhD firstname.lastname@example.org|
|Principal Investigator: Juan Rodrigo, MD.PhD|
|Clínica Universitaria de Navarra||Recruiting|
|Contact: José Ignacio Herrero Santos, MD.PhD email@example.com|
|Principal Investigator: José Ignacio Herrero Santos, MD.PhD|
|Hospital Marqués de Valdecillas||Recruiting|
|Contact: Carmen Fariñas, MD.PhD firstname.lastname@example.org|
|Principal Investigator: Carmen Fariñas, MD.PhD|
|Hospital Virgen del Rocío||Recruiting|
|Contact: Elisa Cordero Matía, MD.PhD email@example.com|
|Principal Investigator: Elisa Cordero Matía, MD.PhD|
|Hospital Universitario La Fe||Recruiting|
|Contact: Mario Blanes, MD.PhD firstname.lastname@example.org|
|Principal Investigator: Mario Blanes, MD.PhD|
|Principal Investigator:||Julián de la Torre Cisneros, MD||Hospital Universitario Reina Sofía, Córdoba, Spain|
|Study Chair:||José M. Aguado, MD, PhD||Hospital Universitario 12 de Octubre, Madrid|